Targeting mGluR group III for the treatment of neurodegenerative diseases - 11/11/23
Abstract |
Glutamate, an excitatory neurotransmitter, is essential for neuronal function, and it acts on ionotropic or metabotropic glutamate receptors (mGluRs). A disturbance in glutamatergic signaling is a hallmark of many neurodegenerative diseases. Developing disease-modifying treatments for neurodegenerative diseases targeting glutamate receptors is a promising avenue. The understudied group III mGluR 4, 6–8 are commonly found in the presynaptic membrane, and their activation inhibits glutamate release. Thus, targeted mGluRs therapies could aid in treating neurodegenerative diseases. This review describes group III mGluRs and their pharmacological ligands in the context of amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, and Huntington's diseases. Attempts to evaluate the efficacy of these drugs in clinical trials are also discussed. Despite a growing list of group III mGluR-specific pharmacological ligands, research on the use of these drugs in neurodegenerative diseases is limited, except for Parkinson’s disease. Future efforts should focus on delineating the contribution of group III mGluR to neurodegeneration and developing novel ligands with superior efficacy and a favorable side effect profile for the treatment of neurodegenerative diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Group III mGluRs activation modulates glutamate release in neurodegeneration. |
• | Many ligands have been synthesized with various potency and efficacy. |
• | Ligands are either specific or non-specific to a group III mGluR subtype. |
• | Group III mGluR ligands have been extensively studied for Parkinson’s disease. |
Abbreviations : AC, AD, Aβ, ALS, ADHD, BBB, CNS, CSF, CA, cAMP, CRD, CYP450s, Elfn1, GPCRs, GIRK, GABA, HD, Htt, HTS, iNOS, iGluR, MHC II, mGluR, MEK, MAPK/ERK, NMDA, NAMs, NFTs, PVN, PD, PI3K/Akt, PAMs, PET, ROS, TNF-α, US FDA, VFD, VGCC, WT
Keywords : Glutamate, MGluR, GPCR, Neurodegeneration, Motor function, Cognitive function
Plan
Vol 168
Article 115733- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?